[Featured Stock] HLB Surges on News of Passing FDA Clinical Trial Inspection for Liver Cancer Drug

HLB is showing strong performance.

As of 9:47 AM on the 18th, HLB was trading at 78,800 won, up 16,500 won (26.48%) from the previous trading day.

HLB's liver cancer drug candidate, Rivoceranib, has passed the clinical trial site inspection, a hurdle it had previously failed. This is being seen as a green light for its challenge for approval in the United States.

On the 18th, HLB announced that it received a "No Action Indicated (NAI)" rating in the FDA's Bioresearch Monitoring Inspection (BIMO). NAI means "passed."